Endothelin-1 Levels in Patients with Paget's Disease of Bone

Abstract

A locally accelerated bone turnover is the pathophysiological basis of Paget's disease of bone (PD) and may result in severe bone deformations and pain. Affected bone sites are hypervascularized. Secreted endothelial products such as endothelin-1 (ET-1), influence bone metabolism. We investigated a possible correlation between ET-1 plasma concentrations and bone metabolism in patients with PD and whether ET-1 plasma levels are regulated by i. v. bisphosphonate treatment. Plasma ET-1 levels were determined in 22 patients with PD and found to be significantly (p = 0.006) elevated (0.75 ± 0.48 fmol/ml) compared to 19 healthy controls (0.20 ± 0.24 fmol/ml). In a group of five patients with PD, plasma ET-1 levels were determined before and after treatment with i. v. pamidronate. On the average, ET-1 levels decreased by 21 % after pamidronate infusions (p = 0.045). The results suggest that bone metabolism in pagetic bone affects endothelial cell metabolism and may also be modulated by endothelial cell products. ET-1 plasma levels may indicate PD activity.

Key words

Paget's disease - endothelin-1 - bone densitometry - bone turnover markers - bisphosphonates

References

• 1 Alam A S, Gallagher A, Shankar V, Ghatei M A, Datta H K, Huang C L, Moonga B S, Chambers T J, Bloom S R, Zaidi M. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption.  Endocrinology. 1992;  130 3617-3624
• 2 Alvarez L, Ricos C, Peris P, Guanabens N, Monegal A, Pons F, Ballesta A M. Components of biological variation of biochemical markers of bone turnover in Paget's bone disease.  Bone. 2000;  26 571-576
• 3 Cawley M I. Complications of Paget's disease of bone.  Gerontology. 1983;  29 276-287
• 4 Cherian R A, Haddaway M J, Davie M W, McCall I W, Cassar-Pullicino V N. Effect of Paget's disease of bone on areal lumbar spine bone mineral density measured by DXA, and density of cortical and trabecular bone measured by quantitative CT.  Br J Radiol. 2000;  73 720-726
• 5 Coessens B C, Miller V M, Wood M B. Endothelin induces vasoconstriction in the bone vasculature in vitro: an effect mediated by a single receptor population.  J Orthop Res. 1996;  14 611-617
• 6 Cook G J, Blake G M, Marsden P K, Cronin B, Fogelman I. Quantification of skeletal kinetic indices in Paget's disease using dynamic 18F-fluoride positron emission tomography.  J Bone Miner Res. 2002;  17 854-859
• 7 Eckhoff M, Klift M, Kroon H, Cooper C, Hofman A, Pols H, Papapoulos S. Paget's disease of bone in the Netherlands: A population-based radiological and biochemical survey - the Rotterdam Study.  J Bone Miner Res. 2004;  19 566-570
• 8 Fogelman I, Bessent R G, Turner J G, Citrin D L, Boyle I T, Greig W R. The use of whole-body retention of Tc-99 m diphosphonate in the diagnosis of metabolic bone disease.  J Nucl Med. 1978;  19 270-275
• 9 Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.  Cancer Res. 2002;  62 6538-6544
• 10 Frelin C, Guedin D. Why are circulating concentrations of endothelin-1 so low?.  Cardiovasc Res. 1994;  28 1613-1622
• 11 Gonzalez D C, Mautalen C A. Short-term therapy with oral olpadronate in active Paget's disease of bone.  J Bone Miner Res. 1999;  14 2042-2047
• 12 Kasperk C, Helmboldt A, Borcsok I, Heuthe S, Cloos O, Niethard F, Ziegler R. Skeletal site-dependent expression of the androgen receptor in human osteoblastic cell populations.  Calcif Tissue Int. 1997;  61 464-473
• 13 Kasperk C H, Borcsok I, Schairer H U, Schneider U, Nawroth P P, Niethard F U, Ziegler R. Endothelin-1 is a potent regulator of human bone cell metabolism in vitro.  Calcif Tissue Int. 1997 b;  60 368-374
• 14 Kitano Y, Kurihara H, Kurihara Y, Maemura K, Ryo Y, Yazaki Y, Harii K. Gene expression of bone matrix proteins and endothelin receptors in endothelin-1-deficient mice revealed by in situ hybridization.  J Bone Miner Res. 1998;  13 237-244
• 15 Lariviere R, Lebel M. Endothelin-1 in chronic renal failure and hypertension.  Can J Physiol Pharmacol. 2003;  81 607-621
• 16 Laroche M, Delpech B, Bernard J, Constantin A, Mazieres B. Measurement of bone mineral density by dual X‐ray absorptiometry in Paget's disease before and after pamidronate treatment.  Calcif Tissue Int. 1999;  65 188-191
• 17 Masukawa H, Miura Y, Sato I, Oiso Y, Suzuki A. Stimulatory effect of endothelin-1 on Na-dependent phosphate transport and its signaling mechanism in osteoblast-like cells.  J Cell Biochem. 2001;  83 47-55
• 18 Mathieu M N, Hamroun D, Launay J M, Chevillard C. Human bone marrow platelet progenitors express and release endothelin-1.  J Cardiovasc Pharmacol. 1998;  31 (Suppl 1) 509-511
• 19 Meunier P J, Coindre J M, Edouard C M, Arlot M E. Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue.  Arthritis Rheum. 1980;  23 1095-1103
• 20 Michel R P, Langleben D, Dupuis J. The endothelin system in pulmonary hypertension.  Can J Physiol Pharmacol. 2003;  81 542-554
• 21 Miyazaki T, Hirose N, Kawamura J, Kageyama Y, Iikuni K, Yanagishita T. A case of generalized Paget's disease of bone complicating high output heart failure.  Nippon Naika Gakkai Zasshi. 1983;  72 47-54
• 22 Owen M. Marrow stromal stem cells.  J Cell Sci. 1988;  10 (Suppl) 63-76
• 23 Roodman G D. Paget's disease and osteoclast biology.  Bone. 1996;  19 209-212
• 24 Roux C, Gennari C, Farrerons J, Devogelaer J P, Mulder H, Kruse H P, Picot C, Titeux L, Reginster J Y, Dougados M. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.  Arthritis Rheum. 1995;  38 851-858
• 25 Rubanyi G M, Botelho L H. Endothelins.  FASEB J. 1991;  5 2713-2720
• 26 Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, Verbruggen A, De Roo M. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET.  J Nucl Med. 1997;  38 1970-1976
• 27 Schneider J G, Tilly N, Hierl T, Sommer U, Hamann A, Dugi K, Leidig-Bruckner G, Kasperk C. Elevated plasma endothelin-1 levels in diabetes mellitus.  Am J Hypertens. 2002;  15 967-972
• 28 Shioide M, Noda M. Endothelin modulates osteopontin and osteocalcin messenger ribonucleic acid expression in rat osteoblastic osteosarcoma cells.  J Cell Biochem. 1993;  53 176-180
• 29 Stern P H, Tatrai A, Semler D E, Lee S K, Lakatos P, Strieleman P J, Tarjan G, Sanders J L. Endothelin receptors, second messengers, and actions in bone.  J Nutr. 1995;  125 2028-2032
• 30 Tarquini R, Perfetto F, Tarquini B. Endothelin-1 and Paget's bone disease: is there a link?.  Calcif Tissue Int. 1998;  63 118-120
• 31 Thiebaud D, Jaeger P, Gobelet C, Jacquet A F, Burckhardt P. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.  Am J Med. 1988;  85 207-212
• 32 Tilly N, Schneider J G, Leidig-Bruckner G, Sommer U, Kasperk C. Endothelin-1 levels in patients with disorders of the thyroid gland.  Exp Clin Endocrinol Diabetes. 2003;  111 80-84
• 33 Tsukahara H, Hori C, Hiraoka M, Yamamoto K, Ishii Y, Mayumi M. Endothelin subtype A receptor antagonist induces osteopenia in growing rats.  Metabolism. 1998;  47 1403-1407
• 34 Vane J. Endothelins come home to roost.  Nature. 1990;  348 673
• 35 Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels.  J Hypertens. 1988;  6 (Suppl) 188-191
• 36 Yin J J, Mohammad K S, Kakonen S M, Harris S, Wu-Wong J R, Wessale J L, Padley R J, Garrett I R, Chirgwin J M, Guise T A. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.  Proc Natl Acad Sci USA. 2003;  100 10954-10959
• 37 Ziegler R, Holz G, Rotzler B, Minne H. Paget's disease of bone in West Germany. Prevalence and distribution.  Clin Orthop. 1985;  194 199-204